Abstract
Time in Range is a new concept in Diabetology, defining the percentage of the length of time in which the patient stays within a predetermined range of blood glucose. Electronic devices, from which the concept of Time in Range derived, help promote a better comprehension of these procedures, and may lead to a decrease in glycemic variability and to a lower risk of complications. It may also ease the control and adjustments in the treatment of diabetes. Therefore, the application of the Time in Range concept could generate a better diabetes control.
 Diabetes Mellitus is a chronic metabolic disease caused by hyperglycemia due to changes related to insulin production and action. It has high morbidity and mortality and high prevalence and may affect several age groups. Currently, its classification is based on its etiology, with the most common diagnoses being pre-diabetes, type 1, type 2 and gestational diabetes. It should be investigated early in patients who have risk factors such as obesity and physical inactivity. It is diagnosed by alterations in fasting or random glucose measurement, oral glucose tolerance test and glycated hemoglobin. Its control and monitoring should be based on glycemic stability. Even more mechanisms are being developed to help the patient in the control of blood glucose, avoiding risks of acute and chronic complications, which can be severe and limiting.
Highlights
Introduction[7] Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020 American Diabetes Association Diabetes Care 2020
Allowing treatment adjustments at the time of acute glucose change. Will this new parameter associated with technological advances, which facilitates the control of the patient with diabetes, effectively reduce the complications caused by uncontrolled blood glucose?
This study aims to evaluate the beneficial effects of maintaining glycemic values within a specific and predetermined target, minimizing glucose variations
Summary
[7] Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020 American Diabetes Association Diabetes Care 2020. The International Diabetes Federation (IDF) estimates that by 2040 there will be around 642 million individuals with DM (1 in 10 adults), including 23.2 million cases only in Brazil [1]. It is a chronic metabolic disease caused by elevated blood glucose, leading to what we call hyperglycemia. Since 1997 DM can be classified according to its etiology, and no longer by its treatment, into several types, the most common being DM1 (mediated by autoimmune or idiopathic process), DM2, gestational DM and the rarer types such as MODY. (Maturity onset diabetes of the Young), endocrinopathies, drug-induced, associated with genetic diseases, among others [2]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
